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ABSTRACT
Inflammation is a potent inducer of tumorigenesis. Increased DNA damage
or loss of genome integrity is thought to be one of the mechanisms linking
inflammation and cancer development. It has been suggested that NF-κB-induced
microRNA-146 (miR146a) may be a mediator of the inflammatory response. Based
on our initial observation that miR146a overexpression strongly increases DNA
damage, we investigated its potential role as a modulator of DNA repair. Here, we
demonstrate that FANCM, a component in the Fanconi Anemia pathway, is a novel
target of miR146a. miR146a suppressed FANCM expression by directly binding to the
3’ untranslated region of the gene. miR146a-induced downregulation of FANCM was
associated with inhibition of FANCD2 monoubiquitination, reduced DNA homologous
recombination repair and checkpoint response, failed recovery from replication stress,
and increased cellular sensitivity to cisplatin. These phenotypes were recapitulated
when miR146a expression was induced by overexpressing the NF-κB subunit p65/
RelA or Helicobacter pylori infection in a human gastric cell line; the phenotypes were
effectively reversed with an anti-miR146a antagomir. These results suggest that
undesired inflammation events caused by a pathogen or over-induction of miR146a
can impair genome integrity via suppression of FANCM.

INTRODUCTION

including RelA/p65. It is a pleiotropic transcription factor
that can exert profound effects on the cellular immune state
by coordinating the expression of numerous downstream
targets [2, 3]. MicroRNA-146a (miR146a), recognized
as a gene targeted by NF-κB, has been implicated in a
variety of cellular functions, particularly in pathological
conditions, such as inflammation and cancer [4–6].
Chronic inflammation caused by a variety of pathogens
such as Helicobacter pylori (H. pylori) can presumably

Chronic inflammation is believed to be a causative
factor for tumorigenesis. NF-κB is a crucial regulator of
the inflammatory response. Its constitutive or transient
activation enables genetic alterations and oncogene
activation, and confers cancer-promoting potential to cells
[1]. NF-κB forms multiple homodimeric- or heterodimeric
complexes with Rel-like domain-containing proteins,
www.impactjournals.com/oncotarget

45976

Oncotarget

induce the long term expression of NF-κB and miR146a
[7–9]. This study investigated the potential influence of
H. pylori infection, activation of NF-κB, and miR146a on
cellular genome integrity and tumorigenesis.
MicroRNAs (miRNAs) are small non-coding
RNAs with approximately 20–24 nucleotides in length
that repress gene expression, usually by targeting the
3ʹ-untranslated regions (3′UTRs) of specific mRNAs.
Over the past decade, in silico screening of the sequencing
database combined with reporter gene-based assays has
led to the discovery of miRNAs targeting genes of interest.
Mounting evidence suggests that the functions of a number
of key factors involved in DNA repair are also regulated
by miRNAs.
The Fanconi anemia (FA)-associated DNA damage
response pathway is a crucial DNA repair mechanism
that resolves DNA interstrand crosslinked (ICL) lesions
and stalled replication forks [10]. A key regulatory event
in the pathway is the monoubiquitination of Fanconi
anemia complementation group D2 (FANCD2), which is
induced by an E3 ubiquitin ligase complex consisting of
8 FA proteins, including Fanconi anemia group M protein
(FANCM) [11]. Monoubiquitinated FANCD2 forms foci at
damaged lesions that co-localizes with DNA repair factors
such as FANCI, BRCA1, and RAD51 [12]. Among the
several reported roles of monoubiquitinated FANCD2
is recruiting the carboxy-terminal binding proteininteracting protein (CtIP) nuclease, which induces end
resection at double strand breaks, a step required for DNA
homologous recombination repair (HR) and replication
fork recovery [13–15]. FANCD2 is also essential in the
removal and bypass of ICL-lesions by DNA replication
machineries [16]. In addition to being part of the FA core
complex, FANCM forms a complex with FA-associated
protein 24 KDa (FAAP24)-MHF1-MHF2, each of which
is required for recruitment of the FA core complex at
chromatin and FANCD2 monoubiquitination. FAAP24
is required for the DNA-binding and chromatin loading
abilities of FANCM in vitro [17]. FANCM also exhibits
ATP-dependent replication fork remodeling and branch
migration activities using model fork structures in vitro,
which may be needed for stabilizing DNA replication forks
during the ICL repair [18, 19]. The fork remodeling and
branch migration activities are enhanced by MHF1-MHF2
in vitro [20–22]. The FANCM-FAPP24 complex also
plays an important role in regulating ICL-induced, ATRmediated checkpoint [23, 24]. The roles of FANCM likely
extend beyond the canonical FA pathway, suggested by the
roles of FANCM orthologs in other organisms; additional
information on this topic is summarized in a recent review
article [25]. Overall, FANCM plays multiple roles in
genome maintenance during replication and DNA repair.
Here, we show that FANCM stability is directly
regulated by miR146a. The overexpression of miR146a
or artificial activation of NF-κB drastically suppressed
FANCM expression, and was associated with impaired
www.impactjournals.com/oncotarget

damage-inducible FANCD2 monoubiquitination, HR
repair, and increased cellular sensitivity to hydroxyurea
(HU) and cisplatin. The physiological significance of this
pathway was supported by the observation that miR146a
expression was induced by H. pylori infection, which
led to reduced FANCM expression and FANCD2 foci
formation. These data suggests the aberrant activation of
inflammation-induced miR146a can compromise genome
integrity by suppressing FANCM expression.

RESULTS
miR146a directly targets the 3ʹUTR of FANCM
It is becoming well-accepted that inflammationinduced miR146a is associated with cancer development
[4–6, 26]. Our initial analysis of miR146a showed that its
overexpression strongly elicited DNA damage in HeLa
(human cervical adenocarcinoma) and GES-1 cells (human
gastric epithelial cells) upon treatment with the replication
stress inducer HU and the DNA ICL-inducing agent
cisplatin, as measured by g-H2AX foci staining (Figure 1A
and Supplementary Figure S1A, respectively). Consistent
with the increased damage, cells expressing miR146a
were more sensitive to HU and cisplatin (Figure 1B and
Supplementary Figure S1B, respectively). Moreover, coexpression of miR-146a antagomir effectively reversed
these phenotypes, suggesting that these effects were
indeed mediated by miR146a. Together, these data
suggest that overexpressing miR146a may impair genome
integrity.
In an attempt to search for the relevant targets of
miR146a in DNA Damage Response (DDR) or DNA
repair, we utilized the TargetScan algorithm (MIT;
release 6.2). This method identified several DDR genes
as potential targets of miR146a, including BRCA1 and
FANCM. Indeed, BRCA1 was previously identified
as a miR146a target [27], validating our bioinformatic
approach. To determine whether their effect of miR-146a
on DNA damage response was mediated via its effect
on FANCM, we cotransfected HeLa and GES-1 cells
with miR-146a and/or miR-146a-insensitive FANCAM
expression plasmid. Our results showed that the nontargetable FANCM rescued the HU-induced g-H2AX
foci formation (Supplementary Figure S2A) and cellular
sensitivity to HU (Supplementary Figure S2B). We also
observed similar reversion when miR-146a-insensitive
BRCA1 was expressed. Interestingly, when we expressed
both FANCM and BRCA1 simultaneously, we did not see
further rescue, indicating that FANCM and BRCA1 may
have overlapping roles in the phenotype that we are seeing.
Subsequent TargetScan analysis predicted that
miR146a targeted two sequences found between
nucleotides (nt) 704 and 711 and between nt 755 and 761
on the human FANCM 3′UTR sequence (Figure 2A). To
confirm the interaction of miR146a with these predicted
sites and the subsequent repression of FANCM, we
45977
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Figure 1: Increase of DNA damage sensitivity by miR146a. (A) Two days after transfection of HeLa or GES-1 cells with miR146a

alone or together with anti-miR146a, the cells were treated with 5 mM HU for 16 h to detect residual γ-H2AX. Results are shown as the
mean ± SD (n = 3); **P < 0.01. (B) HeLa and GES-1 cells were transfected with control, miR146a, and miR146a plus anti-miR146a, and
were then exposed to increasing concentrations of HU for 5 hr. The viability of treated cells was examined using the clonogenic survival
assay. Results are shown as the mean ± SD (n = 3); **P < 0.01.
www.impactjournals.com/oncotarget
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performed a 3′UTR luciferase reporter assay. The
relative luciferase activity of the construct with wildtype 3′UTR of FANCM significantly repressed following
the transfection of miR146a (Figure 2B). In contrast,
the repression of relative luciferase activity was clearly
abrogated when single (M1 and M2) and especially double
(M3) conserved sites were deleted in the FANCM 3′UTR.
This indicates that these two seed regions are functional
as miR146a targets sites, exerting additive effects on each
other. Accordingly, the MT3 mutant was shown to be
nonfunctional as a target of miR146a due to the complete
loss of both target sites.
Next, to examine the evolutionary conservation
of the identified target sites across species, the human
FANCM 3′UTR of 878 nt in length (GenBank accession
number: NM_020937.3) was aligned with 100 vertebrate
species using the algorithms provided by the UCSC
genome browser (https://genome.ucsc.edu/index.html).
Surprisingly, alignment data showed that the FANCM
3′UTR was only conserved between primates, and that
sequence differences with the other species were such
that full sequence alignment was not allowed. While the
two target sites of miR146a was relatively well conserved
between primates (Supplementary Figure S3, red open
box), neither target site was detected in species other than
primates. These results suggest that the miR146a-mediated
regulation of FANCM expression was introduced to the
primate-specific FA pathway as a relatively late event in
vertebrate evolution.
TargetScan algorithm (MIT; release 6.2) was further
used to generate a selective miRNA library for screening
(Supplementary Table S1). The analysis identified a
total of six miRNAs as candidates, each of which was
subjected to reverse screening for gene silencing effects on
FANCM expression using a luciferase reporter gene assay
(Figure 2C). The results showed that miR146a expression
led to remarkably lower luciferase activity compared
to control miRNA, whereas weak or non-statistically
significant effects were observed with the other tested
miRNAs. Consistently, miR146a overexpression
significantly reduced endogenous FANCM protein level
in HeLa cells (Figure 2D). The effects of miR146a on
endogenous FANCM expression was further confirmed
by comparing its protein levels in two human cancer cell
lines, HeLa and U2OS (osteosarcoma) cells, and two
human gastric cell lines, HGC-27 (carcinoma) and GES-1
(immortalized normal) cells, after transfecting the cells
with miR146a or a negative control miRNA. As shown in
Figure 2E, miR146a expression, which was also confirmed
using RT-qPCR (Figure 2E, bottom), led to dramatic
decreases in FANCM protein levels in all of the tested
cells. BRCA1 protein expression was also downregulated,
consistent with data from a previous study [27]. Moreover,
expressing anti-miR146a in MCF7, HeLa and GES-1
cells led to increases in both FANCM and BRCA1 levels
(Supplementary Figure S4). FANCM mRNA expression
www.impactjournals.com/oncotarget

was also reduced when miR146a was overexpressed
(Figure 2F), indicating that miR146a post-transcriptionally
downregulates FANCM. These results demonstrate that
miR146a down-regulates FANCM expression by directly
targeting the 3′UTR of its transcript.

miR146a expression inversely correlates with
FANCM protein levels in several breast cancer
cell lines
Garcia et al. [27] reported that miR146a was
abnormally overexpressed in several breast cancer cells.
We chose three of the cell lines described in that report to
compare the expression patterns of endogenous miR146a
and FANCM protein using RT-qPCR and Western blot
analysis, respectively. While the MCF-7 and MDAMB-231 cell lines express wild type BRCA1, MDAMB-436 cells carry mutated BRCA1 (5396 + 1G > A in
the splice donor site of exon 20) (http://research.nhgri.nih.
gov/bic/) [28] Western blot analysis of FANCM expression
showed that its protein levels were significantly lower in
the MDA-MD-231 and MDA-MB-436 cell lines compared
to the MCF-7 control cell line (Figure 2G). These results
suggest that miR146a expression in breast cancer cell lines
is inversely correlated with FANCM protein levels.
When DNA repair does not properly operate in
response to DNA ICLs or replication stress, it frequently
gives rise to genome-wide chromosomal breaks,
leading to genomic instability. To examine the effect
of miR146a on genomic integrity, array comparative
genomic hybridization was performed using human
fibroblast GM00637 cells after transfecting with miR146a
or a control miRNA. We found that chromosomal
abnormalities were detected as chromosomal gains
(dots over 0.5) and losses (dots below -0.5) that were
widely distributed throughout the entire genome of
miR146a-expressing cells (Figure 2H and Supplementary
Figure S5), indicating that overexpressing miR146a causes
chromosomal instability.

miR146a targeting FANCM impairs FANCD2
monoubiquitination
Loss of FANCM leads to reduced FANCD2ubiquitination [17, 29]. Therefore, we assessed
whether overexpressing miR146a interferes with the
monoubiquitination of FANCD2 in HeLa and GES-1 cells
following treatment with HU, which causes replication
stress and activates the FA pathway. Consistent with
the reduction in FANCM levels, miR146a expression
in HeLa or GES-1 cells led to a significant decrease
in
monoubiquitinated
FANCD2
(FANCD2-Ub)
level, compared to a control miRNA (Figure 3A and
Supplementary Figure S6A, respectively). The effects
of miR146a were effectively reversed by co-transfecting
anti-miR146a (Figure 3A), or by expressing exogenous
45979
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Figure 2: miR146a directly targets FANCM. (A) Schematic diagrams show the sequence and position of predicted miR146a

binding sites in the FANCM 3′UTR. Single- (M1 and M2) and double- (M3) deletion mutations of the miR146a target sites were shown.
The seed resion of miR146a is in red. (B) FANCM 3′UTR-WT and FANCM 3′UTR-MT1-3 were cotransfected with miR146a into HeLa
cells. Luciferase activity was measured 24 h after transfection. Data represent the mean ± SD (n = 3); **P < 0.01. (C) HeLa cells were
cotransfected with the FANCM 3′UTR luciferase reporter vector along with the candidate miRNAs, which were predicted by Targetscan
v6.2, or the miRNA-negative control (miR-Ctrl). Results are shown as the mean ± SD (n = 3). (D) The levels of FANCM protein were
measured by western blotting after transfection of miR146a into a number of cell lines as indicated. (E) Western blot analysis using cell
extracts was performed to detect cellular levels of FANCM and BRCA1 after transfecting indicated cells with miR146a (top). In parallel,
the transfected cells were subjected to RNA extraction, followed by RT-qPCR to measure the amount of miR146a after transfection. The
relative amount of miR146a was quantified and shown as the mean ± SD (n = 3); **P < 0.01 (bottom). (F) Expression of FANCM mRNA
in miR146a transfected cells was quantitated using real-time qPCR. Results are shown as the mean ± SD (n = 3); **P < 0.01. (G) Three
different breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-436, were cultured and cell extracts were analyzed for evaluating
miR146a (left) and FANCM expression (right) using Western blotting and RT-qPCR, respectively. Results are shown as the mean ±
SD (n = 3); **P < 0.01. (H) Array CGH profiles of human fibroblast GM00637 cells transfected with miR146a versus control miRNA.
Chromosomal regions above or below the red dotted line indicate gains or losses of corresponding genomic positions, respectively.
www.impactjournals.com/oncotarget
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FANCM cDNA that does not harbor the miR146abinding 3′UTR (Figure 3B), suggesting that the effects
are specific to miR146a and FANCM. Consistent with
these results, both HeLa and GES-1 cells transfected with
miR146a exhibited defective formation of FANCD2 foci
compared to cells containing control miRNA, as shown
by the decreased number of cells with foci (>5 foci) and
these effects were rescued by anti-miR146a or FANCM
cDNA expression (Figure 3C, 3D and Supplementary
Figure S6B). These findings suggest that reduced
FANCM caused by miR146a leads to impaired FANCD2
monoubiquitination and FANCD2 foci formation.
In addition to playing a role in inducing FANCD2monoubiquitination, FANCM is also required for inducing
replication protein A (RPA) phosphorylation and Chk1
activation in response to ICL-inducing agents [23, 24].
Consistent with this finding, expressing miR146a led to
reduced phosphorylation of Chk1 and RPA, which was
reversed by FANCM cDNA or anti-miR146a expression
(Figure 3E and 3F, respectively). These results confirm
that miR146a expression influences the physiological
functions of FANCM during DDR.

transactivate miR146a transcription (Figure 5A). NFκB activation in HeLa cells through p65 overexpression
was also confirmed by the NF-κB luciferase assay, where
transcription of the firefly luciferease was turned on by
the binding of activated NF-κB to its cis-acting element
in the promoter of this reporter gene (Supplementary
Figure S7). These results suggest that overexpressing
p65 functionally mimics NF-κB activation. Indeed, like
miR146a, p65 overexpression in HeLa cells inhibited
expression of the luciferase reporter gene carrying wild
type FANCM 3ʹ-UTR, whereas co-transfection with the
p65 construct and anti-miR146a alleviated this inhibitory
effects of NF-κB (Figure 5B), indicating that the effects
of NF-κB on FANCM are exerted via miR146a. Western
blot analysis showed a prominent reduction in FANCM
protein levels, upon overexpression of the p65 subunit,
which was recovered by co-transfection of p65 and
anti-miR146a (Figure 5C). Consistent with the reduced
FANCM levels, overexpressing p65 led to a reduction
in FANCD2 monoubiquitination (Figure 6A) and foci
formation (Figure 6B) in HeLa and GES-1 cells. These
phenotypes were reversed by co-transfection with antimiR146a, indicating that the effect of NF-κB on FANCD2
monoubiquitination and foci formation rely on the
regulatory axis of NF-κB-miR146a-FANCM. Consistent
with the role of FANCM in the checkpoint response, p65
overexpression led to decreased Chk1 (Ser317) and RPA
phosphorylation, which was reversed by an antagomir
of miR146a (Figure 6C). Similar to what we observed
in miR146a-transfected cells, p65 overexpression led
to delayed recovery from a stalled replication fork, as
demonstrated by the shortening of red fluorescent CldU
tracts in p65-overexpressing cells compared to control
cells (Figure 6D).
We found that p65 overexpression strongly induced
γ-H2AX foci, and interestingly, the co-expression of antimiR146a reduced the phenotype, in HeLa and GES-1
cells (Figure 6E). Consistent with the increased damage,
p65-overexpressing cells were sensitive to HU treatment,
and the effects were partially or largely alleviated by
anti-miR146a treatment (Figure 6F). These data suggest
that aberrantly overexpressed NF-κB promotes genomic
instability by up-regulating miR146a, which suppresses
FANCM expression.

miR146a attenuates replication fork restart
Given the known roles of FA proteins in modulating
replication fork recovery and DNA replication origin
firing, we determined the effects of miR146a on
replication fork restart. To this end, we analyzed the DNA
fiber spreading patterns of miR146a-transfected GES-1
cells after pulse-labeling the cells sequentially with IdU
(green fluorescence) and CldU (red fluorescence) before
and after 5-h HU treatment, respectively (Figure 4A). The
results showed that nascent CldU tract length distribution
from stalled replication forks was mainly shorter tracts in
miR146a-expressing cells compared to control miRNAtransfected cells (Figure 4B), indicative of attenuated
replication fork restart. This miR146a effect is consistent
with a previous study demonstrated that FANCM-deficient
cells exhibited defective replication fork restart [30].

Activation of NF-κB recapitulates miR146a
expression in suppressing the FA pathway
There is a wealth of evidence supporting the fact
that NF-κB up-regulates miR146a expression in various
cell types such as those involved in immune responses
and in cancer development [4–6]. To test whether the
effects of miR146 overexpression described above could
be recapitulated by NF-κB activation, we analyzed the
effects of overexpressing the NF-κB RelA/p65 subunit
after transfecting HeLa or GES-1 cells with the RelA/
p65 expression construct. First, RT-qPCR confirmed that
the overexpressed p65 subunit significantly upregulated
miR146a expression compared to the control vector,
indicating that overexpressed RelA/p65 was successfully
integrated into the active dimeric form of NF-κB to
www.impactjournals.com/oncotarget

H. pylori mediates down-regulation of FANCM
NF-κB is constitutively activated during
inflammatory responses triggered by H. pylori infection
[7–9, 31]. In addition, miR146a was recently identified
as a target gene upregulated by H. pylori infection [32,
33]. Therefore we postulated that H. pylori infection
may affect FANCM protein levels by upregulating
NF-κB and miR146a in the GES-1 cells. First, to confirm
that the inflammatory responses in GES-1 cells were
induced by H. pylori infection, we assessed the cellular
level of the interleukin (IL)-8 transcript using RT-qPCR
45982
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Figure 3: Effect of miR146a on FANCD2 monoubiquitination and the FA pathway. (A and B) HeLa cells were transfected

with miR146a in the absence or presence of anti-miR146a (A) or miR146a-insensitive FANCM cDNA (B). After a 48 h transfection, the cells
were treated with 5 mM HU for 5 h. The protein levels of FANCM and FANCD2 were measured by western blotting. Monoubiquitinated
FANCD2 is indicated as the upper band of doublet protein bands corresponding to FANCD2. (C and D) After HeLa cells underwent the
same treatment as (A and B) cells were analyzed for FANCD2 foci formation. DAPI was used for nuclear staining. Results are shown as
the mean ± SD (n = 3); **P < 0.01. (E and F) Indicated cells were treated with 5 mM HU for 5 hr. Cell lysates were analyzed by Western
blotting with antibodies against pCHK1-S317, CHK1, pRPA-S4/8, and RPA.
www.impactjournals.com/oncotarget
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and verified that its cellular level increased by ~80-folds
after H. pylori infection compared to an untreated control
(Supplementary Figure S8). IL-8 is one of the downstream
genes whose expression is turned on by activated NF-κB
when H. pylori infects gastric mucosa epithelial cells
[34–36]. Next, to determine the cellular FANCM level,
GES-1 cell lysates were analyzed by western blotting after
24 h of H. pylori infection. Consistent with the results
from p65 overexpression in Figure 5C, FANCM protein
levels were notably down-regulated in H. pylori-infected
cells compared to untreated control cells (Figure 7A, left).
Parallel RT-PCR analysis revealed that miR146a was upregulated by H. pylori infection by ~3.5 fold compared
to the control (Figure 7A, right). Importantly, the effects
of H. pylori infection on FANCM expression were
alleviated by the simultaneous treatment of anti-miR146a
(Figure 7B), suggesting that these effects were largely due
to miR146a expression.

Consistent with the reduction in FANCM levels,
FANCD2 monoubiquitination and foci formation were
reduced upon H. pylori infection (Figure 7C). In contrast,
the effects of H. pylori on FANCD2 were largely reversed
by transfecting anti-miR146a during H. pylori infection, as
shown by recovery of both FANCD2 monoubiquitination
and foci formation (Figure 7D). These findings indicate
that H. pylori-induced inflammatory responses downregulate FANCM expression by increasing cellular
miR146a, whose expression is under the control of NF-κB.

DISCUSSION
In this study, we demonstrated that FANCM is
a direct target of miR146a. Through bioinformatic
searches, we identified the 3′UTR of FANCM as a binding
site of miR146a, and confirmed this experimentally.
Overexpression of miR146a suppressed the steady state

Figure 4: Effect of miR146a on replication fork restart. (A) Schematic of a single DNA fiber analysis is depicted. For DNA fiber

analysis, after being transfected with miR146a or a control miRNA, GES-1 cells were labeled with IdU for 20 min, followed by exposure
to HU for 5 hr and chased with CldU for 40 min. (B) Representative images of spread DNA fibers from miR146a-expressing cells versus
control cells (top). Nascent track length distribution curves were plotted after measuring the length of CldU tracts from DNA fibers with
two consecutive colors of green (IdU) and red (CldU).
www.impactjournals.com/oncotarget
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level of FANCM, which was reversed by an antagomir.
We showed that miR146a overexpression disrupted
the several known FANCM-dependent processes, such
as: FANCD2 monoubiquitination/foci formation, the

FANCM-mediated checkpoint response, replication
fork stability, and cellular resistance to cisplatin and
HU. miR146a overexpression also led to the reduced
RAD51 foci formation and increased double-strand

Figure 5: Effect of NF-κB on FANCM expression. (A) HeLa or GES-1 cells were transfected with the p65 expression construct and

miR146a levels in the indicated cells were determined using RT-qPCR analysis. Results are shown as the mean ± SD (n = 3); **P < 0.01.
(B) Luciferase reporter gene construct carrying the wild type or mutated 3ʹ-UTR of FANCM was cotransfected with p65 cDNA or p65
cDNA plus anti-miR146a, as well as a control vector into HeLa cells. Luciferase activity was measured 24 hours after the transfection.
Data represent the mean ± SD (n = 3); **P < 0.01. (C) HeLa or GES-1 cells were transfected with p65 construct in a combination of
Anti-miR146a or a control miRNA, and indicated protein levels were determined by western blotting (top). Quantitative densitometry of
FANCM protein expression is shown below, expressed as the mean ± SD (n = 3).
www.impactjournals.com/oncotarget
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Figure 6: NF-κB reiterating miR146a function in the FA pathway and replication fork restart. (A) Two days after

transfection of cells with p65 cDNA and anti-miR146a in combination as indicated, cells were treated with 5 mM HU for 5 h. The levels
of FANCM and p63 proteins, and FANCD2 ubiquitination were measured by western blotting. (B) After undergoing the same treatment as
(A) HeLa cells were analyzed for FANCD2 foci formation. Results are shown as the mean ± SD (n = 3); **P < 0.01. (C) Under the same
conditions described in (A) cell lysates were analyzed by western blotting with antibodies against pCHK1-S317, CHK1, pRPA-S4/8, RPA,
and GFP. Right, quantitation of pCHK1-S317 and pRPA-S4/8 expression. Results are shown as the mean ± SD (n = 3). (D) GES-1 cells
transfected with p65 construct were applied to DNA fiber analysis. Resulting images of DNA fibers of p65-overexpressing cells compared
with control cells (top). CldU tract length distribution was determined (bottom). (E) HeLa or GES-1 cells with the same treatment as A were
subjected to γ-H2AX detection. Results are shown as the mean ± SD (n = 3); **P < 0.01. (F) HeLa and GES-1 cells were transfected with
p65 construct and Anti-miR146a in combinations as indicated and were treated with different doses of HU for 5 hr. Cell survival thereafter
was measured using clonogenic survival assay. Results are shown as the mean ± SD (n = 3); **P < 0.01.
www.impactjournals.com/oncotarget
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break formation, although these phenotypes could be
attributed to both impaired FANCD2 activation as well
as BRCA1 expression. BRCA1 was previously reported
to be a target of miR146a in a study which showed that
miR146a overexpression reduced HR repair by BRCA1
downregulation [27]. Thus, we used BRCA1 as an
internal control throughout our studies. Interestingly, we
found that the effects of miR146a were recapitulated by
overexpressing the p65 subunit of NF-κB, and that these
effects were significantly reversed by the concomitant

expression of anti-miR146a, suggesting that the effects
caused by the NF-κB activation are largely due to
miR146a. In order to utilize a more physiological inducer
of miR146a expression, we employed H. pylori infection
as a tool. Indeed, H. pylori led to a significant induction
of miR146a, as well as reduced levels of FANCM and
FANCD2 activation, which were reversed by antimiR146a. Thus, our findings show that genome integrity
is influenced by the functional link among pathogeninduced inflammation, NF-κB, and miR146a.

Figure 7: H. pylori-mediated FANCM regulation. (A) After infection of GES-1 cells with H. pylori, FANCM and BRCA1 protein levels
were determined by western blotting (left). The effect of H. pylori on miR146a was determined by RT-qPCR (right). Results are shown as
the mean ± SD (n = 3); **P < 0.01. (B) GES-1 cells infected with H. pylori were transfected with anti-miR146a, and FANCM and BRCA1
protein levels were determined by western blotting. (C) H. pylori -infected GES-1 cells were treated with 5 mM HU for 5 hours, FANCD2
monoubiquitination (left) and its foci forming activity (right) were examined by western blotting and immunostaining, respectively. Data
respresent the mean ± SD (n = 3). **P < 0.01. (D) H. pylori-infected GES-1 cells were transfected with anti-miR146a and treated with
5 mM HU for 5 hours. FANCD2 monoubiquitinating activity (left) and subsequent foci formation (right) were measured by western blotting
and fluorescent cell staining, respectively. Results are shown as the mean ± SD (n = 3). **P < 0.01.
www.impactjournals.com/oncotarget
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In light of the fact that implication of miR146a
in tumorigenesis has been heavily discussed [5, 6,
26, 27, 37], our results further strengthen the notion
that the aberrant expression of miR146a can increase
tumorigenesis. Our finding that the breast cancer cell
lines expressing a high level of miR146a failed to express
the FANCM protein is particularly intriguing. Our work
shows that the downregulation of FANCM at least in
part contributes to the role of miR146a in compromising
genome integrity. Although the statistically significant
inverse correlation between miR146a and FANCM needs
more extensive comparative studies in various types of
cancer cells with clinical manifestation, our study provides
the first line of evidence showing a negative correlation
between endogenous miR146a and FANCM expression in
breast cancer cell lines.
Our analysis suggests that the miR146a-mediated
regulation of FANCM may be restricted to primates, based
on the poorly conserved sequence within the FANCM
3′UTR. This finding suggests that sequences corresponding
to the FANCM 3ʹUTR might have undergone massive
species-specific gene rearrangements such as insertions
and deletions and base substitutions after speciation since
early vertebrate evolution [38]. Moreover, the alignment
of the region spanning two miR146a target sites and their
flanking regions were not applicable except in primates,
nor were two target sites detected in the other species than
primates through a BLAST search. This indicates that a
regulation strategy for FANCM via miR146a has emerged
as a relatively recent gain-of-function in the evolutionary
history of vertebrate FANCM. As per the regulation of the
FA pathway by miRNA, a several other FA-related genes
such as BRCA1 and RAD51 were shown to be targeted by
miRNAs [39–41].
Perhaps the most intriguing aspect of our work is the
connection between pathogenic infection and disruption
of genome integrity. Pathogens such as H. pylori have
long been suspected as a potential carcinogen. Individuals
afflicted with chronic infection of this microbe are at
high risk for gastric cancer or gastric mucosa-associated
lymphoid tissue lymphoma [42–44]. We found that miR146a
expression was up-regulated by both H. pylori infection
and NF-κB activation, the latter of which is regarded as a
critical link between inflammation and cancer. While the
contribution of inflammatory cytokines to inflammationlinked cancer susceptibility is now widely accepted, the
DNA damage accompanying chronic inflammation has
gradually gained attention as it can lead to gene mutations
that can cause cancer [28, 45]. During inflammation, proinflammatory cytokines such as TNF-a, IL-1β, and IL-6,
serve as the main way of communication between cells in
different tissues and immune cells and trigger intracellular
signaling cascades whose main feature is NF-κB activation
[46–49]. miR146a is a well-known NF-κB-dependent gene
but has also been reported to downregulate several signaling
mediators involved in inflammatory responses such as TNF
receptor-associated factor 6 (TRAF6) and IL-1 receptorwww.impactjournals.com/oncotarget

associated kinase 1 (IRAK1) that are located upstream of
NF-κB activation, thus exerting a negative feedback loop
for modulating NF-κB activity [4, 50, 51], which prevents
constitutive activation of NF-κB during inflammatory
response. On the other hand, NF-κB can be activated
during the host cell response to bacterial infection (e.g.,
H. pylori in our study). H. pylori’s cell wall component
peptidoglycan which is injected into gastric epithelial
cells during infection, is recognized by the intracellular
pattern recognition molecule, NOD1, eliciting the signaling
cascade to activate NF-κB, which occurs independently
of cytokine-triggered signaling cascades [7, 33, 52]. Our
results demonstrate that GES-1 cells successfully responded
to H. pylori infection, expressing IL-8 whose transcription
is activated by NF-κB. Although additional studies on H.
pylori-induced dampening of FA pathway activation in more
physiological settings are needed, our finding that H. pylori
influenced FANCM levels provides an understanding of the
mechanism behind H. pylori-linked carcinogenesis. There
are several ways to explain the mechanisms underlying
genomic instability caused by H. pylori: i) H. pylori
infection impairs mismatch repair and base excision repair
by down-regulating component molecules [53, 54]; ii)
H. pylori infection generates reactive oxygen species,
causing oxidative damage of the DNA and genomic
instability [55]; iii) specific oncogene activation in
precancerous patient tissue samples is associated with
double-strand breaks caused by H. pylori infection and
the activation of DNA-damage checkpoints [56–58].
The disturbance of the FA pathway by H. pylori may not
be critical for maintenance of the genomic integrity of
terminally-differentiated gastric epithelial cells in the
G0 phase. However, this pathogen would compromise
the genomic integrity if the infection occurs in actively
proliferating gastric epithelial progenitors [59]. Subsequent
exposure to genotoxins such as ICL-inducing agents, which
gastric epithelial cells have even higher chance to take
up as food ingredients may also foster the gastric cancer
development.
In summary, we demonstrated that miR146a
decreased the FANCM protein level, thereby disabling
FANCD2 activation upon DNA damaging agent treatment.
Furthermore, we uncovered an important role of miR146a
in NF-κB- and H. pylori- induced genomic instability. Our
work suggests that dysregulated NF-κB activation and
persistent H. pylori infection, both of which upregulate
miR146a expression, can compromise genome integrity
and potentially contribute to tumorigenesis in part by
suppressing the DDR involving FANCM.

MATERIALS AND METHODS
Cell culture and treatment
The human cervical adenocarcinoma cell line HeLa,
immortalized human normal gastric epithelial mucosa cell
line GES-1, human gastric carcinoma cell line HGC-27,
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and human osteosarcoma bone morphogenetic cell line
U2OS were purchased from the American Type Culture
Collection (ATCC, Rockville, MD) and maintained as
recommended: all of the cell types were cultured in
Dulbecco’s Modified Eagle’s medium (Invitrogen, CA)
supplemented with 10 % heat-inactivated fetal bovine
serum (Invitrogen), 100 units/ml penicillin, and 100 µg/
ml streptomycin sulfate (Invitrogen), and maintained
in a humidified incubator containing 5% CO2 at 37oC.
To induce replication fork stalling or ICL damage,
exponentially growing cells were exposed to 5 mM HU
or 1 mM cisplatin and allowed to recover at 37oC for 5 h.

were transfected with miR146a, anti-miR146a or RelA/
p65 expression construct. After 24 h of transfection, the
luciferase assay was performed using the dual luciferase
reporter assay system (Promega, WI) according to the
manufacturer’s instructions. Luciferase activity was
quantified using a luminometer (Glomax, Promega).

NF-κB luciferase reporter assay
HeLa cells were seeded at a concentration of
5 × 105 cells/well in 24-well plates. After overnight
culture and reaching 80% confluence, the cells in
each well were transiently transfected with 1 μg DNA
consisting of pGL4.32 (luc2P/NF-κB-RE/Hygro) as a
reporter (Promega), pRL-TK, as well as the RelA/p65
expression construct, in serum-free medium according to
the manufacturer’s protocol. After 12 h, the transfection
mix was removed and replaced with complete medium.
Twenty-four hours after co-transfection, cells were
harvested and luciferase activity was determined using the
Luciferase Assay System (Promega, E1500).

H. pylori culture and infection
The H. pylori strain 26695 was obtained from
HpKTCC (H. pylori Korean Type Culture Collection,
Jinju, South Korea). The bacteria was grown in Brucella
broth containing 10% fetal bovine serum, 10 µg/
ml vancomycin, 25 µg/ml nalidixic acid and 5 µg/ml
amphotericinB, and maintained in a humidified incubator
containing 10% CO2 at 37oC. GES-1 cells were seeded
at 10 × 105 cells/100 mm plate and grown to 70–80%
confluency. H. pyroli infected the GES-1 cells at 100
MOI multiplicity of infection for 24 h. The infection was
monitored by the release of IL-8.

miRNA and plasmid transfection
Hsa-miR146a duplex and negative control miRNA
were purchased from Bioneer (Daejeon, South Korea).
Cells were transfected with 50 nM miRNA using
lipofectamine RNAiMax (Invitrogen) according to the
manufacturer’s instructions. For rescue experiments, a
miR146a inhibitor (anti-miR146a) was used. Full-length
BRCA1 and FANCAM were cloned into pcDNA3-HA and
pCMV-Flag vector, respectively, to generate mammalian
expression vector. For experiments measuring NF-κBmediated miR146a regulation, pcDNA HA-p65 vector
was used. pcDNA-HA empty vector and scrambled
oligonucleotide were used as negative controls.

Antibodies
The antibodies used for Western blotting were
as follows: FANCM (sc-98710), FANCD2 (sc-20022),
BRCA1 (sc-642), β-actin (sc-47778; Santa Cruz, CA),
RPA (NA18; Calbiochem, CA), phosphor-RPA(S4/
S8) (A300-245A; Bethyl Lab), CHK1 (2G1D5; Cell
Signaling, MA) and phosphor-CHK1(S317) (AF2054;
R&D System, MN). FANCD2 foci were detected by
immunofluorescence staining using an anti-FANCD2
antibody (AB2187; Abcam). γ-H2AX foci were
visualized by immunofluorescence staining using anti-γH2AX mouse monoclonal antibody (JBW301; Upstate
Biotechnology, NY). RAD51 foci were detected by
immunofluorescence staining using mouse monoclonal
anti-RAD51 (14B4) (ab213; Abcam, MA).

Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl
[pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM
dithiothreitol, 1 mM phenylmethanesulfonyl fluoride,
10 µg/ml leupeptin and 10 µg/ml aprotinin). Equal
amounts of cell or tissue extracts were separated by
6–12% SDS-PAGE gels followed by electrotransfer onto
a PVDF membrane (Life Sciences, NJ). Western blots
were performed by using the appropriate primary and
secondary antibodies. The amounts of FANCM protein
were quantified using Scion Image software (Scion
Corp., MD).

miRNA luciferase reporter assay
Segments of the 3′UTR of FANCM containing
putative miR146a binding sites were cloned into pMIRREPORT firefly luciferase vector (Applied Biosystems,
CA). Deletion mutants of predicted miR146a binding
sites were made using the GENEART Site-Directed
Mutagenesis kit (Invitrogen). For the luciferase activity
assay, pMIR-REPORT luciferase vectors containing wild
type or mutant 3′UTRs of FANCM and pRL-TK vector
containing Renilla luciferase as a transfection control
were co-transfected into HeLa cells using Lipofectamine
2000 (Invitrogen), and subsequently, the same cells
www.impactjournals.com/oncotarget

Immunofluorescence staining
Cells cultured on cover slips were treated with
5 mM hydroxyurea or 1 mM cisplatin, allowed to recover
for adequate times and then fixed in 4% paraformaldehyde
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and 98% methanol, followed by permeabilization with
0.3% Triton X-100. Then coverslips were blocked in 5%
BSA in PBS and immunostained with primary antibodies
and secondary antibodies conjugated with Alexa Fluor 488
(green, Molecular Probe, CA) or Alexa Fluor 594 (red,
Molecular Probe). After washing, the coverslips were
mounted onto slides using a Vectashield mounting medium
with DAPI (Vector Laboratories, CV). Fluorescence
images were taken using a confocal microscope (Zeiss
LSM 510 Meta; Carl Zeiss) and analyzed with Zeiss
microscopic imaging software ZEN (Carl Zeiss).

the time of seeding for the plating efficiency of treated
cells over untreated cells. Cell survival results are reported
as the mean value ± SD for three independent experiments.

RNA extraction and reverse rranscriptionquantitative real-time PCR (RT-qPCR)

Array comparative genomic hybridization (CGH)
analysis was performed using the Nimblegen Human
CGH 12 × 135 K whole-genome tiling v3.1 Array (Agilent
Technologies, CA). Human genomic DNA (1 µg) from
human fibroblast GM00637 cells which were transfected
with miR146a and reference DNA samples from control
cells were independently labeled with fluorescent dyes
(Cy3/Cy5), co-hybridized at 65°C for 24 h, and then
subjected to the array. The hybridized array was scanned
using NimbleGen MS200 scanner (NimbleGen Systems
Inc., WI) with 2 µm resolution. Log2-ratio values of the
probe signal intensities were calculated and plotted versus
genomic position using Roche NimbleGen NimbleScan
v2.5 software. Data are displayed and analyzed in Roche
NimbleGen SignalMap software and CGH-explorer v2.55.

Total RNA was isolated from cultured cells,
mouse tissues, and prostate cancer samples using TRIzol
reagent (Invitrogen). For quantitation of FANCM and
IL-8 mRNA, cDNA was synthesized using 1 μg total
RNA, random hexamer (Promega) and M-MLV reverse
transcriptase (Invitrogen). Real-time PCR analysis was
performed using the SYBR green-based fluorescent
method (SYBR premix Ex Taq kit, TaKaRa Bio) and
the MX3000P® qRT-PCR system (Stratagene, CA) with
specific primers. Primers used for real-time PCR are as
follows: fancm forward, 5ʹ-tgctcttcacaggagtggtg-3ʹ and
fancm reverse, 5ʹ-gggcacacaggaacttgact-3ʹ; IL-8 forward,
5ʹ-TTGGCAGCCTTCCTGATTTC-3ʹ
and
reverse
5ʹ-AACTTCTCCACAACCCTCTG-3ʹ. To quantify
miRNAs, cDNA was synthesized using Mir-XTM miRNA
first-strand synthesis and SYBR qRT-PCR kit (Clontech)
according to the manufacturer’s instructions. HasmiR146a-MI0000477 was used as primer for real-time
qPCR. The quantity of transcripts was calculated based
on the threshold cycle (Ct) using the delta-delta Ct method
that measures the relative of a target RNA between two
samples by comparing them to a normalization control
RNA (gapdh or U6).

DNA fiber analysis

Statistical analysis

GES-1 cells were labeled with 25 μM 5-iodo-2ʹdeoxyuridine (IdU) for 20 min, followed by exposure to
5 mM HU for 5 h, and chased with 250 μM 5-chloro-2ʹdeoxyuridine (CldU) for 40 min. After labeled cells were
harvested, DNA fibers were spread as previously described
[60] before fluorescent staining for IdU and CldU tracts
(with primary antibodies for IdU, (mouse α-BrdU (Sigma)
at 1:25 dilution); and for CldU (rat α-BrdU (Sigma) at a
1:400 dilution) and secondary antibodies: anti-mouse IgG
conjugated with AlexaFluor 488 and Cy3-conjugated
anti-rat IgG, respectively, from Invitrogen). Fibers were
visualized under a confocal microscope (Zeiss LSM 510
Meta) and analyzed using Zeiss microscopic imaging
software ZEN (Carl Zeiss).

Data in all of the experiments are presented as the
mean ± standard deviation (SD) Statistical comparisons
were performed using two-tailed paired Student’s t-test,
where p < 0.01(**) was considered statistically significant.
Analyses were performed using GraphPad Prism software
(GraphPad software) and Excel (Microsoft).

Array comparative genomic hybridization
analysis
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